

CUD DRUG REPURPOSING

Ibrutinib as a Potential Therapeutic for Cocaine Use Disorder

Spencer B. Huggett, Ph.D¹

Jeffrey S. Hatfield²

Joshua D. Walters, Ph.D.²

John E. McGeary, Ph.D³

Justine W. Welsh, M.D.⁴,

Trudy F. C. Mackay, Ph.D, FRS²

Robert R. H. Anholt, Ph.D²

Rohan H.C. Palmer, Ph.D¹

Affiliations:

1. *Behavioral Genetics of Addiction Laboratory, Department of Psychology at Emory University, Atlanta, GA, USA*

2. *Department of Genetics and Biochemistry and Center for Human Genetics, Clemson University, Greenwood, SC, USA*

3. *Providence Veterans Affairs Medical Center, and Department of Psychiatry and Human Behavior, Brown University*

4. *Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, USA*

Corresponding Authors:

Spencer B. Huggett, PhD

Behavioral Genetics of Addiction Laboratory – Department of Psychology

Emory University, 36 Eagle Row

Atlanta, GA 30322, USA

Emails: Spencer.B.Huggett@emory.edu; Phone: 1 (404) 727-6636; Fax: 1 (404) 727-0372;

Roha H.C. Palmer, PhD

Behavioral Genetics of Addiction Laboratory – Department of Psychology

Emory University, 36 Eagle Row

Atlanta, GA 30322, USA

Emails: Rohan.Palmer@Emory.edu; Phone: 1 (404) 727-7340; Fax: 1 (404) 727-0372;

CUD DRUG REPURPOSING

1 **ABSTRACT**

2
3 Cocaine use presents a worldwide public health problem with high socioeconomic cost. Current
4 treatments for cocaine use disorder (CUD) are suboptimal and rely primarily on behavioral
5 interventions. To explore pharmaceutical treatments for CUD, we analyzed genome-wide gene
6 expression data from publically available human brain tissues (midbrain, hippocampus and
7 prefrontal cortex neurons) from 71 individuals (mean age = 39.9, 100% male, 36 with CUD and
8 35 matched controls). We leveraged the L1000 database to investigate molecular associations
9 between neuronal mRNA profiles from 825 repurposable compounds (e.g., FDA approved) with
10 human CUD gene expression in the brain. We identified 16 compounds that were negatively
11 associated with CUD gene expression patterns across all brain regions ($p_{\text{adj}} < 0.05$), all of which
12 outperformed current targets undergoing clinical trials for CUD (all $p_{\text{adj}} > 0.05$). We tested the
13 effectiveness of these compounds using independent transcriptome-wide *in vitro* (neuronal
14 cocaine exposure; n=18) and *in vivo* (mouse cocaine self-administration; prefrontal cortex,
15 hippocampus and midbrain; n = 12-15) datasets. Among these medications, Ibrutinib
16 demonstrated negative associations with both neuronal cocaine exposure and mouse cocaine self-
17 administration. To obtain experimental confirmation of therapeutic effects of Ibrutinib on CUD,
18 we used the *Drosophila melanogaster* model, which enables highthroughput quantification of
19 behavioral responses in defined genetic backgrounds and controlled environmental conditions.
20 Ibrutinib altered cocaine-induced changes in startle response and reduced the occurrence of
21 cocaine-induced seizures (n = 61-142 per group; sex: 51% female). Our results identify Ibrutinib,
22 an FDA approved medication, as a potential therapeutic for cocaine neurotoxicity.

23

CUD DRUG REPURPOSING

24 INTRODUCTION

25 Approximately 18.1 million people use cocaine globally each year¹ and roughly 30% of
26 those users reside in the United States² (US). In the US, nearly 1 million individuals meet criteria
27 for cocaine use disorder² (CUD) and 13% of the individuals in North American substance use
28 treatment facilities are treated for CUD¹. Cocaine use increases risk for cardiovascular disease,
29 seizures, and mental health disorders and contributes to roughly 40% of drug-related emergency
30 room visits in the US³. Cocaine toxicity occurs via multiple mechanisms in nearly all tissue
31 types⁴. Since 1999, cocaine-involved overdose deaths have increased by 416% in the US and
32 resulted in 15,883 deaths in 2019⁵. To date, there are no medications approved by the Food and
33 Drug Administration (FDA) for human CUD or cocaine toxicity.

34 Developing treatments for substance use disorders is a key priority of the National
35 Institute on Drug Abuse. While behavioral treatments for CUD exist, they have limited efficacy
36 and are plagued by high dropout rates⁶. Over 20 pharmaceutical medications are currently being
37 tested for clinical trials for CUD. Most of these medications include antidepressants,
38 antipsychotics, psychostimulants, cognitive enhancing drugs, anxiolytics, repurposed
39 medications for other substance use disorders, anticonvulsants/muscle relaxants, and dopamine
40 agonists⁷. These treatments generally have mixed efficacy and often only demonstrate effects in
41 particular subpopulations. Medications for cocaine toxicity are also limited. Emergency room
42 practitioners rely on beta-blockers for cocaine- cardiotoxicity⁸ and benzodiazapines for cocaine
43 neurotoxicity⁹ (e.g., seizures). Many candidate compounds for treating CUD and cocaine toxicity
44 rely on repurposing existing medications, leveraging knowledge of cocaine's pharmacology,
45 and/or the biological mechanisms underpinning cocaine pathology.

CUD DRUG REPURPOSING

46 The molecular neuropathology of CUD is characterized by persistent cellular and
47 molecular adaptations across multiple brain regions, particularly in the mesocorticolimbic
48 “reward” pathway. Molecular neuroadaptations in this pathway mediate reward, motivation,
49 behavioral control, memory formation, incentive salience, cue, drug and stress-induced drug
50 taking/relapse. One approach to investigate the neuromolecular correlates underlying CUD (and
51 potentially cocaine neurotoxicity) is to examine gene expression profiles in post-mortem brain
52 tissue by comparing individuals with CUD to matched cocaine-free controls. Currently, three
53 studies are publicly available that assess CUD gene expression profiles in key addiction brain
54 regions: the dorsal-lateral prefrontal cortex¹⁰ (dlPFC), hippocampus¹¹ and midbrain¹².
55 Previously, medications that consistently target gene expression across meso-cortico-limbic brain
56 regions have demonstrated robust effects for reducing binge drinking in mice¹³. Thus, screening
57 medications that target transcriptional patterns across relevant brain regions may help identify
58 FDA-approved therapeutics that could be repurposed for treating CUD.

59 Drug discovery analyses can cut costs and time for developing effective therapeutics,
60 which on average cost \$1.4 billion and take 12-16 years to develop¹⁴. The NIH-funded Library of
61 Integrated Network-based Cellular Signatures (LINCS L1000) database facilitates drug
62 development strategies by indexing over 1.3 million expression profiles resulting from an
63 extensive catalog of more than 48,000 perturbagens (pharmaceuticals, small molecules, shRNAs,
64 cDNAs, and biologics) in over 80 human cell lines¹⁵. This resource allows rapid screening of
65 compounds that may target the molecular mechanisms of a disease.

66 Here, we outline a neuronal mRNA drug-repurposing framework that identifies and
67 validates potential medications for CUD and/or cocaine neurotoxicity (see **Figure 1** for study
68 overview).

CUD DRUG REPURPOSING

69

70 **METHODS**

71 *Drug Discovery Input*

72 Our human sample (n = 71) comprised of publicly available gene expression data from
73 post-mortem brain tissue of individuals with cocaine use disorder (CUD; n = 36) and matched
74 cocaine-free controls (n = 35). Data were obtained from three independent studies
75 (GSM2642566¹⁰; SRA029279¹¹; E-GEOD-54839¹²; Supplementary Table S1). We conducted
76 drug discovery analyses leveraging the L1000 database, which catalogues mRNA expression
77 profiles of human cell types exposed to therapeutic compounds¹⁵.

78 The input for our drug discovery analysis included three categories. The first category
79 included all differentially expressed genes (Benjamini-Hochberg False Discovery Rate (FDR) <
80 0.05) associated with CUD in the dlPFC¹⁶, hippocampus¹⁷ and midbrain¹². Differentially
81 expressed genes might include genes attributed to cocaine-induced toxicity, cardiac
82 complications or psychiatric comorbidities. Thus, our second category focused on the genes
83 related to the behavioral manifestations of CUD, by including the mRNA expression of genes
84 from the cocaine addiction pathway (Kyoto Encyclopedia of Genes and Genomes [KEGG]
85 database). The last category sought to further minimize potential biases of measurement error by
86 employing “landmark” genes (those directly measured from L1000, rather than imputed) that
87 were part of at least one of the first two categories. We refer to the input genes for our drug
88 discovery analysis as CUD genes (Supplementary File S1).

89

90 *Drug Discovery Analyses*

CUD DRUG REPURPOSING

91 Drug discovery analyses utilized the L1000 Connectivity Mapping gene expression
92 profiles from the Library of Integrated Network Based Cellular Signatures (level 5 data from
93 phase I: GSE92742 and phase II: GSE70138). Since the focus of the study was to find
94 repurposable treatments for CUD, we selected all compounds that were FDA approved *or* in
95 stages 1-3 of clinical trials – as listed from the drug repurposing hub website
96 (<https://clue.io/repurposing#download-data>; updated 3/24/2020). We benchmarked our findings
97 with treatments that were currently undergoing clinical trials for CUD and specifically those that
98 were reported on the <https://clinicaltrials.gov/> website.

99 The mechanisms of action for most pharmacological treatments of substance use
100 disorders target neuronal processes. Thus, we focused our drug discovery analysis on two
101 neuronal cell types used in the L1000 database: differentiated neuronal cells and neuronal
102 progenitor cells. In total, we evaluated the potential therapeutic value of 825 compounds, which
103 spanned 3,468 individual neuronal mRNA signatures (*in vitro* gene expression profiles for a
104 compound measured at a particular dose, time, and cell line). For each signature, we estimated a
105 linear Pearson Product-Moment correlation coefficient with the CUD input. Note that not all
106 medications undergoing clinical trials for CUD were included in the human neuronal cell lines
107 from the L1000 database (Supplementary File S2).

108 To identify potential treatments for CUD, we conducted multi-level meta-regressions for
109 all 825 compounds using the metafor package in R¹⁸. Multi-level meta-regression provides a
110 powerful and interpretable framework that can accommodate for complex data-types. Our meta-
111 regressions adjusted for two random effects: human brain region (or study) and the three input
112 categories within studies (e.g. KEGG_{dIPFC}, KEGG_{Hippocampus} etc.). We treated each compound as a
113 fixed-effect incorporating the effect size (r) and sampling variability (se^2_r) for neuronal

CUD DRUG REPURPOSING

114 signatures of a compound. Theoretically, if the transcriptional signature of a compound is
115 negatively associated with a disease, this compound may ‘reverse’ the underlying disease
116 mechanisms and *may* increase the likelihood of demonstrating clinical utility. Hence, we
117 emphasized compounds with negative meta-regression coefficients that also survived correction
118 for multiple testing ($FDR < 0.05$) and defined these compounds as *potential* therapeutics.

119 We then used a computational follow-up approach to prioritize the potential therapeutics
120 identified from our drug discovery analysis using two independent transcriptome-wide datasets.
121 These datasets included a human neuronal cocaine exposure model¹⁹ (SH-SY5Y neuroblastoma
122 cells; GSE71939) and a mouse model of cocaine self-administration²⁰ (GSE110344). The
123 neuronal cocaine exposure dataset included 18 samples that assessed mRNA expression (via
124 microarray) for two time points (6 or 24 hours post exposure) across three doses ($0\mu\text{M}$, $1\mu\text{M}$ and
125 $5\mu\text{M}$; the latter two mimic biologically relevant cocaine levels found in individuals with cocaine
126 abuse). The mouse RNA-sequencing (RNA-seq) data were collected from 12-15 male C57BL/6J
127 mice using similar brain regions to the human samples (ventral tegmental area (VTA),
128 hippocampus and PFC). Mice pressed a lever to receive intravenous infusions of cocaine
129 (1mg/kg ; 2 hour sessions for 2 weeks) or saline. Brain tissue was extracted 24 hours after the last
130 self-administration session and mouse modeling was limited to orthologous genes listed from the
131 mouse genome informatics dataset (<http://www.informatics.jax.org/>).

132 To maintain consistency, we harmonized the data processing and analyses for our
133 validation datasets to resemble the human brain data (see Supplementary Methods). Using multi-
134 level meta-regression, we assessed whether the potential CUD treatments were also negatively
135 associated with the differential expression of the CUD genes in the neuronal cocaine exposure
136 and mouse cocaine self-administration datasets – accounting for dose and time (neuronal

CUD DRUG REPURPOSING

137 exposure data) or brain region (mouse data) as random effects. Results from the computational
138 follow-up were used to prioritize medications for experimental validation.

139

140 *Behavioral assays*

141 *Drosophila melanogaster* (Canton-S B strain) were reared on cornmeal-molasses-yeast
142 medium at 25°C and 70% humidity under a 12h light-dark cycle (lights on at 6:00 am). Cocaine-
143 HCl was obtained from the National Institute on Drug Abuse under Drug Enforcement
144 Administration license RA0443159. Flies were food-deprived for 24 hours followed by a 20
145 minute free-feeding period. During this period, flies consumed one of three food formulations
146 containing either no drugs (n = 66 females, n = 61 males), cocaine only (n = 141 females, n =
147 140 males), or cocaine and Ibrutinib (n = 142 females, n = 132 males). The concentrations of
148 cocaine-HCl and Ibrutinib (Tocris Bioscience; Bristol, UK; Product No: 6813; Batch No:
149 2A/247900) were both 0.16% (w/w). Immediately following exposure, each fly underwent
150 behavioral testing for startle response induced by a mechanical disturbance. A vial housing a
151 single fly was dropped through a chute from a height of 42 cm and then secured in a horizontal
152 position. During the next 45 seconds, the total time spent moving and the occurrence of seizures
153 were recorded. Seizure activity was defined as significant disruption of normal movement with
154 severe tremors and muscle twitching (see Supplementary File S3). While immobile, seizing, or
155 grooming, flies were considered stationary. Startle response data were analyzed using a two way
156 fixed effects factorial ANOVA model: $Y = M + S + T + S \times T + \varepsilon$, where Y is the phenotype,
157 M is the mean, S is sex, T is treatment, $S \times T$ is the sex by treatment interaction, and ε is the
158 residual. We used the type III Sums of Squares due to differing sample sizes across groups. Post-

CUD DRUG REPURPOSING

159 hoc comparisons were performed using Student's *t*-tests. Seizure data were analyzed using
160 Fisher's exact tests in R.

161 RESULTS

162 *Drug Discovery Input*

163 A schematic overview of the study design is presented in **Figure 1**. Prior to our drug
164 discovery analysis we examined the input data. We observed minimal overlap among
165 differentially expressed genes identified across human brain regions (see Supplementary Figure
166 1). Associations among KEGG cocaine addiction genes were modest and sometimes negative
167 ($r_{\text{midbrain_hippocampus}} = -0.31, p = 0.044$; $r_{\text{dlPFC_hippocampus}} = 0.02, p = 0.915$; and $r_{\text{midbrain_dlPFC}} = 0.36,$
168 $p = 0.019$). This heterogeneity and individual variation may be one factor contributing to the
169 difficulty in finding an effective treatment that targets multiple brain regions and is effective for
170 all individuals in a population.

171 *Drug-Discovery Analyses*

172 Our drug discovery analysis discovered 16 medications with gene expression signatures
173 that were negatively associated with gene expression associated with CUD in the midbrain,
174 hippocampus and dlPFC ($p_{\text{adj}} < 0.05$; **Figure 2A**), with diverse pharmacological mechanisms of
175 action (Supplementary Table S2). These medications outperformed the current pharmaceuticals
176 undergoing clinical trials for CUD (**Figure 2B**). Current clinical trial treatments for CUD
177 exhibited more heterogeneity across brain regions and samples than the repurposable
178 medications we identified.

179 Next, we employed a computational follow-up of the 16 potential CUD medications
180 using transcriptome-wide data from preclinical *in vitro* and *in vivo* models. Only one compound,
181 *Ibrutinib*, was negatively associated with neuronal cocaine exposure ($p = 0.001$; $p_{\text{adj}} = 0.019$) and

CUD DRUG REPURPOSING

182 was also trending to reverse gene expression profiles associated with mouse cocaine self-
183 administration ($p = 0.007$; $p_{\text{adj}} = 0.0732$; **Figure 3**). No other medication demonstrated
184 significant evidence among preclinical models (see Supplementary Figure S2). Using
185 correlations between human CUD brain data and the *in vitro* drug discovery data, we found that
186 Ibrutinib may reverse the expression of genes involved in dopaminergic and glutamatergic
187 neurotransmission as well as various immediate early genes, intracellular signaling cascade
188 genes and putative neuroepigenetic transcripts (**Figure 4**).

189 *Validation of potential therapeutic efficacy of Ibrutinib in the Drosophila model*

190 To validate the effectiveness of Ibrutinib as a potential therapeutic for CUD, we
191 evaluated its effects on cocaine-induced phenotypes in the *Drosophila melanogaster* model
192 system. *Drosophila* provides an advantageous model system for studies on cocaine
193 consumption²¹. The *Drosophila* dopamine transporter contains a binding site that can
194 accommodate cocaine²², and exposure to cocaine gives rise to motor responses that resemble
195 behaviors observed in rodents. In addition, flies develop sensitization to repeated intermittent
196 exposure to cocaine^{23,24}.

197 We measured startle behavior and the prevalence of seizure activity in male and female
198 flies following acute consumption of solid food, solid food supplemented with cocaine, or solid
199 food supplemented with cocaine and Ibrutinib. Male flies exposed to cocaine spent less time
200 moving after being subjected to a mechanical startle (**Figure 5A**). This is likely due to the
201 occurrence of cocaine-induced seizures, which were scored as stationary periods. Both male and
202 female flies that consumed Ibrutinib with cocaine spent more time moving than flies that only
203 consumed cocaine (**Figure 5A**). Male flies that consumed Ibrutinib and cocaine showed a
204 significant decrease in the prevalence of seizures ($p = 0.0029$; **Figure 5B**). Fewer cocaine-

CUD DRUG REPURPOSING

205 induced seizures were also observed in Ibrutinib treated females, but this observation did not
206 reach statistical significance since the incidence of cocaine-induced seizures was lower in
207 females than in males. These results confirm that Ibrutinib may be useful as a therapeutic to
208 prevent various neurobehavioral and neurotoxic effects of cocaine use.

209 **Discussion**

210 We used a novel technique to identify and validate potential repurposable medications for
211 CUD or cocaine toxicity. These medications demonstrated more reproducible associations across
212 the brain's reward circuitry than the current medications undergoing clinical trials in the US.
213 Despite the low correlation of gene expression across datasets, Ibrutinib consistently reversed
214 patterns of gene expression observed in brains of individuals with CUD across brain regions and
215 diverse samples as well as across two gold standard preclinical models. Thus, we consider
216 Ibrutinib to be the most promising repurposable medication for CUD identified by our study.
217 Ibrutinib is a Bruton's tyrosine kinase inhibitor and is approved by the FDA for various B cell
218 cancers including chronic lymphocytic leukemia²⁵. While Ibrutinib is not a typical candidate for
219 addiction therapeutics, our study suggests that it may target and reverse the expression of cocaine
220 addiction genes in human meso-cortico-limbic circuitry. Notably, Ibrutinib shares a
221 pharmacological mechanism of action with Terric acid, a compound that reduced binge drinking
222 in mice¹³.

223 Ibrutinib may have therapeutic potential for cocaine neurotoxicity. Our results from the
224 *Drosophila* models suggest Ibrutinib significantly reduces cocaine-induced seizure frequency.
225 While rare, cocaine-induced seizures have a serious and urgent need for treatments²⁶. The precise
226 mechanism by which Ibrutinib may alleviate cocaine neurotoxicity remains unclear. Ibrutinib
227 influences intracellular cascades involved in pro-inflammatory response, Ca⁺ signaling and

CUD DRUG REPURPOSING

228 protein kinase activity^{27, 28}. These processes are also involved in cocaine use^{29, 30}, and cocaine-
229 induced seizures³¹.

230 Most therapeutics for substance use disorders (and drug-induced overdoses) target
231 neurotransmitter receptors. We found that expression of the dopamine transporter (*SLC6A3* or
232 *DATI*) as well as various dopamine and glutamate receptors (*DRD1*, *DRD2*, *GRIN2D*, *GRIN2A*,
233 *GRIN2B*, *GRIA2*) in brains from CUD individuals were negatively associated with the *in vitro*
234 neurotranscriptional signatures of Ibrutinib. These findings are correlative, but illuminate
235 possible pleiotropic mechanisms in which Ibrutinib counteracts the neuropathology of CUD.
236 Finally, both cocaine and Ibrutinib act on the mushroom bodies in the fly brain. These central
237 brain structures are responsible for associative learning and memory³², and experience-dependent
238 behavioral modification³². The mushroom bodies also serve as initiation sites for seizures³³ and
239 drug consumption³⁴.

240 In addition to Ibrutinib, we discovered other potential medications that may counter some
241 of the neuroadaptations of CUD. Some of these compounds may target molecular processes
242 underlying chronic cocaine use. For instance, we found that dopamine reversed the differential
243 expression of CUD genes across brain regions, which may counteract the hypodopaminergic
244 state induced by chronic cocaine use³⁵. A preponderance of the drugs tested seemed to be
245 sensitive to various cardiac complications associated with cocaine use, such as Rivaroxaban,
246 Pinacidil, Iloprost, Gemfibrozil, Bexafibrate and Moxonidine. It is possible that these
247 medications exert a neuroprotective role for cocaine use and may be relevant for cocaine
248 toxicity. Some of these medications may have both health and behavioral benefits. For instance,
249 Moxonidine reduces (cue-induced) cocaine relapse³⁶ and ethanol withdrawal^{37, 38} in rodents. Of
250 note, the pharmacological profiles of the potential CUD medications we identified have shown to

CUD DRUG REPURPOSING

251 reduce various drug use behaviors (PPAR alpha agonists³⁹; PDE4 inhibitors^{40, 41}). Potential CUD
252 medications also influenced catecholamine neurotransmission, potassium channels, hormonal
253 signaling and mitochondrial processes, which have all been implicated in the pathophysiology of
254 cocaine use^{42, 43, 44, 45}. Our results may serve a dual purpose for indirectly unraveling
255 neuromolecular features of human CUD while also identifying specific chemical compounds that
256 may demonstrate clinical utility for cocaine-related outcomes.

257 The results of our study should be interpreted with caution until further validation studies
258 are conducted. We used all extant transcriptome-wide brain data on human CUD, but these
259 sample sizes were small and were ascertained from highly selected cocaine users. Additionally,
260 these data are unable to characterize specific symptoms of CUD and may have bias relating to
261 health and psychiatric comorbidities. We sought to minimize these biases by investigating
262 validated genes from the cocaine addiction (KEGG) pathway as well as integrating tightly
263 controlled experimental cocaine data from preclinical paradigms. Our study benchmarked
264 potential CUD medications against current targets in clinical trials, although we did not have
265 data on various pharmaceuticals that have demonstrated some efficacy for individuals with CUD
266 (e.g., disulfiram⁴⁶; topiramate⁴⁷). The lead repurposable drug from this study, Ibrutinib, may not
267 be an accessible treatment option to many, as it can be costly⁴⁸ and may be associated with side
268 effects⁴⁹. In addition, it is unknown what dose would be most effective and whether negative
269 health consequences arise when combining this medication with cocaine (or crack cocaine). As
270 with other substance use disorders, pharmaceutical interventions for CUD will likely only
271 provide incremental improvement. The most successful treatment will likely require a
272 combination of medication and psychosocial interventions such as cognitive-behavioral therapy,
273 contingency management, and lifestyle modification as a form of relapse prevention⁵⁰. Despite

CUD DRUG REPURPOSING

274 these limitations, Ibrutinib emerges as a promising therapeutic with potential for the treatment of
275 CUD-associated symptoms. In a broader context, our study provides a proof-of-principle for a
276 powerful, flexible and interpretable method that can be used to identify and prioritize
277 therapeutics from genome-wide and transcriptome-wide datasets.

CUD DRUG REPURPOSING

Acknowledgements

We acknowledge the National Institute on Drug Abuse award DP1DA042103 (awarded to RHCP) and DA041613 (awarded to RRHA and TFCM). We are grateful for the LINCS database curators as well as those responsible for the availability of the RNA-sequencing and microarray data. Content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the Department of Veteran Affairs.

Conflict of Interest

The authors declare no conflicts of interest.

CUD DRUG REPURPOSING

References

1. (United Nations publication SNE 19. X 8). World Drug Report. 2019.
2. SAMSHA. (2019). Key Substance Use and Mental Health Indicators in the United States: Results from the 2018 National Survey on Drug Use and Health.
3. Turner C, Chandrakumar D, Rowe C, Santos G, Riley D, Coffin PO. Cross-sectional cause of death comparisons for stimulant and opioid mortality in San Francisco, 2005 - 2015. *Drug Alcohol Depend* 2019;185:305–12.
4. Glauser J, Queen JR. AN OVERVIEW OF NON-CARDIAC COCAINE TOXICITY. *J Emerg Med*. 2007;32(2):181–6.
5. National Institute on Drug Abuse [Internet]. Trends & Statistics: Overdose Death Rates [updated Jan 29 2021; cited February 5th 2021]. Available from: <https://www.drugabuse.gov/drug-topics/trends-statistics/overdose-death-rates>.
6. Dutra L, Stathopoulou G, Basden SL, Leyro TM, Powers MB, Otto MW. A Meta-Analytic Review of Psychosocial Interventions for Substance Use Disorders. *Am J Psychiatry* 2006;14(16):3989–96.
7. Chan B, Kondo K, Freeman M, Ayers C, Montgomery J, Kansagara D. Pharmacotherapy for Cocaine Use Disorder — a Systematic Review and Meta-analysis. *JGIM* 2017;2858–73
8. Vroegop MP, Franssen EJ, Voort PHJ Van Der, Berg TNA Van Den, Langeweg RJ, Kramers C. The emergency care of cocaine intoxications. *Neth J Med* 2009;67(4):122–6.
9. Chen H, Albertson TE, Olson KR. Treatment of drug-induced seizures. *Br J Clin Pharmacol* 2015;81(3):412–9.
10. Ribeiro EA, Scarpa JR, Garamszegi SP, Kasarskis A, Mash DC, Nestler EJ. Gene Network Dysregulation in Dorsolateral Prefrontal Cortex Neurons of Humans with Cocaine Use Disorder. *Sci Rep* 2017;7(1):1–10.
11. Zhou Z, Yuan Q, Mash DC, Goldman D. Substance-specific and shared transcription and epigenetic changes in the human hippocampus chronically exposed to cocaine and alcohol. *PNAS* 2011;108(16).
12. Bannon MJ, Johnson MM, Michelhaugh SK, Hartley ZJ, Halter SD, David JA, et al. A molecular profile of cocaine abuse includes the differential expression of genes that regulate transcription, chromatin, and dopamine cell phenotype. *Neuropsychopharmacology* 2014;39(9):2191–9.
13. Ferguson LB, Ozburn AR, Ponomarev I, Metten P, Reilly M, Crabbe JC, et al. Genome-Wide Expression Profiles Drive Discovery of Novel Compounds that Reduce Binge Drinking in Mice. *Neuropsychopharmacology* 2018;43(6):1257–66.
14. Nosengo N. New tricks for old drugs. *Nature*. 2016;534:314–6.
15. Subramanian A, Narayan R, Corsello SM, Root DE, Wong B, Golub TR, et al. Resource A Next Generation Connectivity Map: L1000 Platform Resource A Next Generation Connectivity Map. *Cell* 2017;171(6):1437-1452.e17.

CUD DRUG REPURPOSING

16. Huggett SB, Stallings MC. Genetic Architecture and Molecular Neuropathology of Human Cocaine Addiction. *J Neurosci* 2020;40(27):5300–13.
17. Huggett SB, Stallings MC. Cocaine’omics: Genome-wide and transcriptome-wide analyses provide biological insight into cocaine use and dependence. *Addict Biol* 2019;25:1–10
18. Viechtbauer W. Conducting Meta-Analyses in R with the metafor Package. *J Stat Softw* 2010;36(3):1–48.
19. Fernandez-Castillo N, Cabana-Dominguez J, Soriano J, Sanchez-Mora C, Roncero C, Grau-Lopez L, et al. Transcriptomic and genetic studies identify NFAT5 as a candidate gene for cocaine dependence. *Transl Psychiatry* 2015;5:1–9.
20. Walker DM, Cates HM, Loh YE, Purushothaman I, Ramakrishnan A, Cahill KM, et al. Cocaine self-administration alters transcriptome-wide responses in the brain’s reward circuitry. *Biol Psychiatry* 2018;84(12):867–80.
21. Kaun KR, Devineni A V, Heberlein U. *Drosophila melanogaster* as a model to study drug addiction. *Hum Genet* 2012;131:959–75
22. Wang KH, Penmatsa A, Gouaux E. Neurotransmitter and psychostimulant recognition by the dopamine transporter. *Nature* 2015;521:322–7
23. Mcclung C, Hirsh J. Stereotypic behavioral responses to free-base cocaine and the development of behavioral sensitization in *Drosophila*. *Curr Biol* 1998;8:109–12.
24. Filošević A, Al-samarai S, Andreti R. High Throughput Measurement of Locomotor Sensitization to Volatilized Cocaine in *Drosophila melanogaster*. *Front Mol Neurosci* 2018;11:1–12.
25. Claro RA De, Mcginn KM, Verdun N, Lee S, Chiu H, Saber H, et al. FDA Approval □: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia. *Clin Cancer Res* 2015;1(3):3586–91.
26. Zou G, Zuo X, Chen K, Zou G, Zuo X, Chen K, et al. Cannabinoids Rescue Cocaine-Induced Seizures by Restoring Brain Glycine Receptor Dysfunction Article Cannabinoids Rescue Cocaine-Induced Seizures by Restoring Brain Glycine Receptor Dysfunction. *CellReports* 2020;30(12):4209-4219.e7.
27. Zhang SQ, Smith SM, Zhang SY, Wang YL. Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma. *Br Jounral Haematol* 2015;170:445–56.
28. Herrera AF, Jacobsen ED. Ibrutinib for the Treatment of Mantle Cell Lymphoma. *Clin Cancer Res* 2014;5365–72.
29. Northcutt AL, Wang X, Baratta M V, Hiranita T, Cochran TA, Pomrenze MB, et al. DAT isn’t all that: cocaine reward and reinforcement require Toll-like receptor 4 signaling. *Mol Psychiatry*. 2015;20:1525–37.
30. Xue B, Guo M-L, Jin D-Z, Mao L-M, Wang JQ. Cocaine facilitates PKC maturation by upregulating its phosphorylation at the activation loop in rat striatal neurons in vivo. *Brain Res* 2012;(816):146–53
31. Du C, Yu M, Volkow ND, Koretsky AP, Fowler JS, Benveniste H. Cocaine Increases the Intracellular Calcium Concentration in Brain Independently of Its Cerebrovascular Effects. *J Neurosci* 2006;26(45):11522–31.

CUD DRUG REPURPOSING

32. Modi MN, Shuai Y, Turner GC. The Drosophila Mushroom Body: From Architecture to Algorithm in a Learning Circuit. *Annu Rev Neurosci* 2020;43:465–84.
33. Saras A, Wu V V., Brawer HJ, Tanouye MA. Investigation of Seizure-Susceptibility in a Drosophila melanogaster Model of Human Epilepsy. *Genetics* 2017;206:1739–46.
34. Highfill CA, Baker BM, Stevens SD, Anholt RRH, Mackay TFC. Genetics of cocaine and methamphetamine consumption and preference in Drosophila melanogaster. *PLoS Genet* 2019;1–24.
36. Smith RJ, Aston-jones G. Alpha-2 adrenergic and imidazoline receptor agonists prevent cue-induced cocaine-seeking. *Biol Psychiatry* 2011;70(8):712–9.
37. Vandergriff J, Kallman MJ, Rasmussen K. Moxonidine, a Selective Imidazoline-1 Receptor Agonist, Suppresses the Effects of Ethanol Withdrawal on the Acoustic Startle Response in Rats. *Biol Psychiatry* 2000;47:874–9.
38. Taksande BG, Kotagale NR, Patel MR, Shelkar GP, Ugale RR, Chopde CT. Agmatine, an endogenous imidazoline receptor ligand modulates ethanol anxiolysis and withdrawal anxiety in rats. *Eur J Pharmacol* 2010;637(1–3):89–101.
39. Foll B Le, Ciano P Di, Panlilio L V., Goldberg SR, Ciccocioppo R. AGONISTS AS PROMISING NEW MEDICATIONS FOR DRUG ADDICTION: PRECLINICAL EVIDENCE. *Curr Drug Targets* 2013;14(7):768–76.
40. Zhong P, Wang W, Yu F, Nazari M, Liu X, Liu Q. Phosphodiesterase 4 Inhibition Impairs Cocaine-Induced Inhibitory Synaptic Plasticity and Conditioned Place Preference. *Neuropsychopharmacology* 2012;37(11):2377–87. Available from: <http://dx.doi.org/10.1038/npp.2012.93>
41. Olsen CM, Liu Q, Road P. Phosphodiesterase 4 inhibitors and drugs of abuse: current knowledge and therapeutic opportunities. *Front Biol* 2017;11(5):376–86.
42. Satta R, Certa B, He D, Lasek AW. Estrogen Receptor β in the Nucleus Accumbens Regulates the Rewarding Properties of Cocaine in Female Mice. *Int J Neuropsychopharmacol* 2018;21:382–92.
43. McCall NM, Kotecki L, Dominguez-lopez S, Marron E, Velasco F De, Carlblom N, et al. Selective Ablation of GIRK Channels in Dopamine Neurons Alters Behavioral Effects of Cocaine in Mice. *Neuropsychopharmacology* 2017;42:707–15.
44. Siciliano CA, Jones SR. Cocaine Potency at the Dopamine Transporter Tracks Discrete Motivational States During Cocaine Self-Administration. *Neuropsychopharmacology* 2017;42(9):1893–904. Available from: <http://dx.doi.org/10.1038/npp.2017.24>
45. Sadakierska-Chudy A, Frankowska M, Filip M. Mitoe-pigenetics and drug addiction. *Pharmacology & Therapeutics* 2014 1;144(2):226–33.
46. Carroll KM, Fenton LR, Ball SA, Nich C, Frankforter TL, Shi J, et al. Efficacy of Disulfiram and Cognitive Behavior Therapy in Cocaine-Dependent Outpatients. *Arch Gen Psychiatry* 2004;61:264–72.
47. Johnson BA, Ait-Daoud N, Wang X-Q, Penberthy K, Javors MA, Seneviratne C, et al. Topiramate for the Treatment of Cocaine Addiction. *JAMA Psychiatry* 2013;70(12):1338–46.

CUD DRUG REPURPOSING

48. Barnes JI, Divi V, Begaye A, Wong R, Coutre S, Owens DK, et al. Cost-effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia in older adults without deletion 17p. *Blood Adv.* 2018;2(15):1946–56.
49. Paydas S. Management of adverse effects/toxicity of ibrutinib. *Crit Rev Oncol / Hematol.* 2019;136:56–63.
50. Id FDC, Id MC, Loreto G, Al D, De R, Id G, et al. Comparative efficacy and acceptability of psychosocial interventions for individuals with cocaine and amphetamine addiction: A systematic review and network meta-analysis. *PLOS Med.* 2018;15(12):1–24.

CUD DRUG REPURPOSING

Figure legends

Figure 1: Overview of the study.

Figure 2: Drug Discovery Results for CUD using Human Brain Data

A) shows repurposable compounds negatively associated with CUD gene expression in the brain (all $p_{adj} < 0.05$). **B)** shows the results of the medications currently undergoing clinical trials for CUD. The x-axis represents the weighted average of a compound's correlation coefficients with the human brain CUD genes and each compound's weighted standard error bars. Also, note that the black circles represent the effect across all brain regions/studies and the points below are color coded by brain region.

Figure 3 Computational Follow-up in Preclinical Models of Cocaine Use

The bottom panel shows associations between Ibrutinib's neuronal signatures and differential expression results from the *in vitro* cocaine neuronal exposure data. The top panel displays the associations between Ibrutinib's neuronal signatures with differential expressed genes from the mouse cocaine self-administration dataset.

Figure 4: Ibrutinib's Neuronal Signatures are Negatively Associated with Cocaine Addiction Genes in the Human Brain

Blue line shows the best fitting line and standard error between CUD gene expression (of KEGG Cocaine Addiction Pathway genes) and neuronal signatures of Ibrutinib (collapsing across dose, time and cell line). Genes were labeled if they were in the negative diagonal of the plot. Differential expression of *FOSB* in the dlPFC was winsorized for visualization purposes.

Figure 5: Ibrutinib Mitigates Cocaine-induced Startle Response and Cocaine-induced Seizures in *Drosophila melanogaster*.

Sample sizes were as follows: (n = 61 (♂ control), 140 (♂ cocaine), 132 (♂ cocaine + Ibrutinib), 66 (♀ control), 141 (♀ cocaine), 142 (♀ cocaine + Ibrutinib) **(A)** Startle response. The percent time out of 45 seconds that each fly spent moving following a 42 cm drop was measured. Male flies exposed to cocaine spent less time moving than flies exposed to untreated food ($p = 2.13 \times 10^{-12}$). Male and female flies exposed to cocaine and Ibrutinib exhibited an increase in the percent of time spent moving compared to flies only exposed to cocaine (♂ $P = 0.000824$, ♀ $P = 0.00246$; two-tailed Student's t-test). Error bars represent standard error. **(B)** Seizure activity during the startle response. The number of flies that exhibited seizure activity during the startle assay was recorded. Male flies exposed to cocaine exhibited more seizure activity than flies exposed to untreated food ($p = 0.0195$; Fisher's exact test). Male flies exposed to cocaine and Ibrutinib exhibited a decrease in the frequency of seizures compared to flies only exposed to cocaine ($p = 0.0029$; Fisher's exact test).



CUD Human Brain Data



Drug Discovery Data




Medication

Control



Neuronal Cocaine Exposure

Mouse Cocaine Self-administration





Experimental Validation




Potential Treatment ?



A**Potential Treatments for CUD****B****Clinical Trial Treatments for CUD**Drug Discovery Compound_Disease Associations (Mean_{Weighted} r)


Computational Follow-up Identifies Ibrutinib as a Potential Medication for CUD




Drug Discovery Compound_Cocaine Associations (Mean_{Weighted} r)

Ibrutinib Reverses Expression of Genes in the Cocaine Addiction Pathway


dIPFC




Hippocampus



Midbrain



A**B**